By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > HER2 inhibitors > Enhertu > Enhertu Dosage
HER2 inhibitors
https://themeditary.com/dosage-information/enhertu-dosage-353.html

Enhertu Dosage

Drug Detail:Enhertu (Fam-trastuzumab deruxtecan [ fam-tras-tooz-ue-mab-der-ux-tee-kan ])

Generic Name: TRASTUZUMAB DERUXTECAN 100mg in 5mL

Dosage Form: injection, powder, lyophilized, for solution

Drug Class: HER2 inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Patient Selection

​Unresectable or Metastatic HER2-Low Breast Cancer

​Select patients for treatment of unresectable or metastatic HER2-low breast cancer with ENHERTU based on HER2 expression (IHC 1+ or IHC 2+/ISH-) [see Clinical Studies (14.2)].

​Unresectable or Metastatic HER2-Mutant NSCLC

​Select patients for the treatment of unresectable or metastatic HER2-mutant NSCLC with ENHERTU based on the presence of activating HER2 (ERBB2) mutations in tumor or plasma specimens [see Clinical Studies (14.3)]. If no mutation is detected in a plasma specimen, test tumor tissue.

Locally Advanced or Metastatic Gastric Cancer

Select patients with locally advanced or metastatic gastric cancer based on HER2 protein overexpression or HER2 gene amplification. Reassess HER2 status if it is feasible to obtain a new tumor specimen after prior trastuzumab-based therapy and before treatment with ENHERTU.

​Additional Patient Selection Information

​Information on FDA-approved tests for the detection of HER2 protein expression, HER2 gene amplification, and activating HER2 mutations is available at: http://www.fda.gov/CompanionDiagnostics.

Recommended Dosage and Schedules

Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine.

Slow or interrupt the infusion rate if the patient develops infusion-related symptoms.

Permanently discontinue ENHERTU in case of severe infusion reactions.

​Premedication

​ENHERTU is moderately emetogenic [see Adverse Reactions (6.1)], which includes delayed nausea and/or vomiting. Administer prophylactic antiemetic medications per local institutional guidelines for prevention of chemotherapy-induced nausea and vomiting.

Recommended Dosage for Metastatic Breast Cancer

The recommended dosage of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

​Recommended Dosage for Unresectable or Metastatic HER2-Mutant NSCLC

​The recommended dosage of ENHERTU is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

Recommended Dosage for Locally Advanced or Metastatic Gastric Cancer

The recommended dosage of ENHERTU is 6.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

Dosage Modifications

Management of adverse reactions may require temporary interruption, dose reduction, or treatment discontinuation of ENHERTU as described in Tables 1 and 2.

Do not re-escalate the ENHERTU dose after a dose reduction is made.

If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

Table 1: Dosage Reduction Schedule
​Dose Reduction Schedule Breast Cancer and NSCLC Gastric Cancer
Recommended starting dose 5.4 mg/kg 6.4 mg/kg
First dose reduction 4.4 mg/kg 5.4 mg/kg
Second dose reduction 3.2 mg/kg 4.4 mg/kg
Requirement for further dose reduction Discontinue treatment. Discontinue treatment.
Table 2: Dosage Modifications for Adverse Reactions
Adverse Reaction Severity Treatment Modification
Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v.5.0).
Interstitial Lung Disease (ILD)/ Pneumonitis
[see Warnings and Precautions (5.1)]
Asymptomatic ILD/pneumonitis
(Grade 1)
Interrupt ENHERTU until resolved to Grade 0, then:
  • if resolved in 28 days or less from date of onset, maintain dose.
  • if resolved in greater than 28 days from date of onset, reduce dose one level (see Table 1).
  • consider corticosteroid treatment as soon as ILD/pneumonitis is suspected.
Symptomatic ILD/pneumonitis
(Grade 2 or greater)
  • Permanently discontinue ENHERTU.
  • Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected.
Neutropenia
[see Warnings and Precautions (5.2)]
Grade 3 (less than 1.0 to 0.5 × 109/L)
  • Interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose.
Grade 4 (less than 0.5 × 109/L)
  • Interrupt ENHERTU until resolved to Grade 2 or less.
  • Reduce dose by one level (see Table 1).
Febrile Neutropenia
[see Warnings and Precautions (5.2)]
Absolute neutrophil count of less than 1.0 × 109/L and temperature greater than 38.3°C or a sustained temperature of 38°C or greater for more than one hour
  • Interrupt ENHERTU until resolved.
  • Reduce dose by one level (see Table 1).
Thrombocytopenia
[see Adverse Reactions (6.1)]
Grade 3 (platelets less than 50 to 25 × 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose.
Grade 4 (platelets less than 25 × 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less.
  • Reduce dose by one level (see Table 1).
Left Ventricular Dysfunction
[see Warnings and Precautions (5.3)]
LVEF greater than 45% and absolute decrease from baseline is 10% to 20%
  • Continue treatment with ENHERTU.
LVEF 40% to 45% And absolute decrease from baseline is less than 10%
  • Continue treatment with ENHERTU.
  • Repeat LVEF assessment within 3 weeks.
And absolute decrease from baseline is 10% to 20%
  • Interrupt ENHERTU.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU.
  • If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose.
LVEF less than 40% or absolute decrease from baseline is greater than 20%
  • Interrupt ENHERTU.
  • Repeat LVEF assessment within 3 weeks.
  • If LVEF of less than 40% or absolute decrease from baseline of greater than 20% is confirmed, permanently discontinue ENHERTU.
Symptomatic congestive heart failure (CHF)
  • Permanently discontinue ENHERTU.

Preparation and Administration

In order to prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is ENHERTU (fam-trastuzumab deruxtecan-nxki) and not trastuzumab or ado-trastuzumab emtansine.

Reconstitute and further dilute ENHERTU prior to intravenous infusion. Use appropriate aseptic technique.

ENHERTU (fam-trastuzumab deruxtecan-nxki) is a hazardous drug. Follow applicable special handling and disposal procedures.1

Reconstitution

  • Reconstitute immediately before dilution.
  • More than one vial may be needed for a full dose. Calculate the dose (mg), the total volume of reconstituted ENHERTU solution required, and the number of vial(s) of ENHERTU needed [see Dosage and Administration (2.2)].
  • Reconstitute each 100 mg vial by using a sterile syringe to slowly inject 5 mL of Sterile Water for Injection, USP into each vial to obtain a final concentration of 20 mg/mL.
  • Swirl the vial gently until completely dissolved. Do not shake.
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be clear and colorless to light yellow. Do not use if visible particles are observed or if the solution is cloudy or discolored.
  • If not used immediately, store the reconstituted ENHERTU vials in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours from the time of reconstitution, protected from light. Do not freeze.
  • The product does not contain a preservative. Discard unused ENHERTU after 24 hours refrigerated.

Dilution

  • Dilute the calculated volume of reconstituted ENHERTU in an intravenous infusion bag containing 100 mL of 5% Dextrose Injection, USP. DO NOT use Sodium Chloride Injection, USP. ENHERTU is compatible with an infusion bag made of polyvinylchloride or polyolefin (copolymer of ethylene and polypropylene).
  • Gently invert the infusion bag to thoroughly mix the solution. Do not shake.
  • Cover the infusion bag to protect from light.
  • If not used immediately, store at room temperature for up to 4 hours including preparation and infusion, or in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 24 hours, protected from light. Do not freeze.
  • Discard any unused portion left in the vial.

Administration

  • If the prepared infusion solution was stored refrigerated (2°C to 8°C [36°F to 46°F]), allow the solution to reach room temperature prior to administration. Cover the infusion bag to protect from light.
  • Administer ENHERTU as an intravenous infusion only with an infusion set made of polyolefin or polybutadiene.
  • Administer ENHERTU with a 0.20 or 0.22 micron in-line polyethersulfone (PES) or polysulfone (PS) filter.
  • Do NOT administer as an intravenous push or bolus.
  • Cover the infusion bag to protect from light during administration.
  • Do not mix ENHERTU with other drugs or administer other drugs through the same intravenous line.
  • First infusion: Administer infusion over 90 minutes.
  • Subsequent infusions: Administer over 30 minutes if prior infusions were well tolerated.
Share this Article
Latest News
Medical News

Seed oils: Omega-6 fatty acids may lower diabetes, heart disease risk

Jun 01, 2025
Type 2 diabetes: Sugary drinks may significantly raise risk
COVID-19: Who do the new vaccine guideline changes affect?
Vitamin D supplements may help slow down aging by 3 years
Aging: Exercise timing, consistency can affect heart and lung fitness
Heart health: Exercise not enough to offset effects of poor sleep
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by